Neurology · Anticonvulsant
The FDA's approval of ANDA214956 for Gabapentin by Ascent Pharm Inc. introduces a new competitor into the market, which could lead to price reductions and shifts in market share. Portfolio teams must evaluate the implications for sales forecasts and competitive dynamics in the gabapentin segment.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/29/2026, 6:32:57 PM
Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of ANDA214956 for Gabapentin by Ascent Pharm Inc. introduces a new competitor into the market, which could lead to price reductions and shifts in market share. Portfolio teams must evaluate the implications for sales forecasts and competitive dynamics in the gabapentin segment. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (7 high-relevance).
Portfolio teams should assess the impact of this approval on gabapentin sales forecasts and competitive positioning. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Neurology · Anticonvulsant, 6 regulatory and 2 competitive items passed relevance filtering for existing gabapentin manufacturers.
The most relevant competitive pressure comes from FDA Grants Approval for Zydus' Edaravone ANDA218349 (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine). This approval may increase competition in the gabapentin market, impacting pricing and market share for existing players.
Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Regulatory pathway relevance (nda). The approval process has been completed, indicating no immediate regulatory concerns for the new entrant, but ongoing compliance will be necessary.
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceAdvancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePartial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Florida ASCENT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNon-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceINcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Approval for Zydus' Edaravone ANDA218349
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDevelopment and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of ANDA214956 for Gabapentin by Ascent Pharm Inc. introduces a new competitor into the market, which could lead to price reductions and shifts in market share. Portfolio teams must evaluate the implications for sales forecasts and competitive dynamics in the gabapentin segment.
Increased competition may pressure pricing and affect revenue for existing players, potentially leading to a decline in market share for established gabapentin products.
The approval process has been completed, indicating no immediate regulatory concerns for the new entrant, but ongoing compliance will be necessary.
Monitor market entry timing and pricing strategies from Ascent Pharm Inc. post-approval.
Track for follow-up milestones; no immediate action required.